Evommune (EVMN) Interest Expenses (2024 - 2026)

Evommune (EVMN) reported Interest Expenses of $4000.0 for Q1 2026, down 69.23% year-over-year from $13000.0 in Q1 2025, and down 55.56% on a QoQ basis from $9000.0 in Q3 2025.

Evommune (EVMN) has 3 years of Interest Expenses data on file, last reported at $4000.0 in Q1 2026.

  • Quarterly Interest Expenses fell 69.23% year-over-year to $4000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26000.0 (changed N/A YoY) and the FY2025 annual result came in at $50000.0, up 35.14% from the prior year.
  • Interest Expenses eased to $4000.0 in Q1 2026 per EVMN's latest filing, from $9000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $17000.0 in Q3 2024 and bottomed at -$1000.0 in Q4 2024.
  • The 3-year median for Interest Expenses is $9000.0 (2025), against an average of $8400.0.
  • The widest annual swing landed in 2025, when Interest Expenses tumbled 47.06%; it then tumbled 69.23% in 2026.
  • Tracing EVMN's Interest Expenses over 3 years: stood at -$1000.0 in 2024, then jumped by 1000.0% to $9000.0 in 2025, then tumbled by 55.56% to $4000.0 in 2026.
  • Per Business Quant, the three latest EVMN Interest Expenses figures stand at $4000.0 (Q1 2026), $9000.0 (Q3 2025), and $13000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 22,854.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -5.50 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 61,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -332,000.00
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 12.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 69.29 Mn
10 Evommune 744.11 Mn 532.65 Mn - 4,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 4,000.00
Mar 31, 2026 4,000.00
Sep 30, 2025 9,000.00
Sep 30, 2025 9,000.00
Mar 31, 2025 13,000.00
Mar 31, 2025 13,000.00
Dec 31, 2024 -1,000.00
Dec 31, 2024 -1,000.00
Sep 30, 2024 17,000.00
Sep 30, 2024 17,000.00